NCT00633542View on ClinicalTrials.gov

Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM)

PHASE3CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

September 30, 2007

Study Completion Date

October 31, 2007

Conditions
Multiple Myeloma
Interventions
DRUG

thalidomide

100 mg/day orally until progression or severe toxicity

DRUG

interferon alpha

3 MU 3 times a week until progression or severe toxicity

Trial Locations (1)

60020

Clinica di ematologia ospedali riuniti ancona università politecnica delle marche, Ancona

All Listed Sponsors
lead

Università Politecnica delle Marche

OTHER

NCT00633542 - Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM) | Biotech Hunter | Biotech Hunter